Andere Sprachen ORIC Pharmaceuticals, Inc.

Aktien

A2P208

US68622P1093

ORIC

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
8,07 ^USD	+5,22 %		-12,19 %	-12,28 %

15.04.	ORIC Pharmaceuticals gibt bekannt, dass die ersten Patienten in drei Erweiterungskohorten der Phase-1b-Studie mit ORIC-114 bei Patienten mit mutiertem NSCLC behandelt wurden	CI
08.04.	ORIC Pharmaceuticals, Inc. stellt präklinische Daten zu zwei Programmen auf der Jahrestagung 2024 der American Association for Cancer Research (AACR) vor	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer	15.04.
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC	15.04.
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC	15.04.
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting	08.04.
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting	08.04.
ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research Annual Meeting	08.04.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	05.04.
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences	04.04.
ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) added to S&P Biotechnology Select Industry Index	18.03.
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11.03.
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates	11.03.
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	11.03.
Oric Pharmaceuticals Insider Sold Shares Worth $648,380, According to a Recent SEC Filing	08.03.
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference	06.03.
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting	05.03.
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting	05.03.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	01.03.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	01.03.
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit	14.02.
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit	14.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ORIC Pharmaceuticals, Inc.

Aktien

A2P208

US68622P1093

ORIC

Andere Sprachen

Filter